As providers and payers navigate an increasingly challenging financial environment, executives are targeting AI tools that show a clear return on investment, according to a report by Klas Research and Bain & Company.
Healthcare AI investment focused on profit margins, ROI: report Read More »
El chatbot ChatGPT ahora construye los prompts para ti – no solo las respuestas Durante años, nos han dicho que “solo escribas un mejor prompt”. Pero si no eres un ingeniero de prompts, eso es como decir “solo escribe mejor código”. Aho …
2025 has been a busy year for Boehringer Ingelheim, which has so far inked at least five hefty partnerships—including its latest one with South Korea’s AimedBio for an antibody-drug conjugate therapy for cancer.
Boehringer Ingelheim Bets up to Nearly $1B in ADC Play With AimedBio Deal Read More »
The company is pursuing a Phase III trial for its topical stem cell-rejuvenating molecule that aims to reactivate hair growth.
Pelage Pharmaceuticals Raises $120 Million To Grow Hair Loss Program Read More »
Top Democrats are airing related concerns that the IT chassis underpinning states’ Medicaid operations may not be robust enough to withstand the added pressure from looming work requirements.
Senate Finance Committee probes Medicaid contractors over faulty systems Read More »
Despite announcing a broad pivot to siRNA earlier this year, Sarepta is following through with an investigational gene therapy: its limb-girdle muscular dystrophy candidate. But the treatment’s path forward, analysts say, is highly uncertain.
Sarepta’s Not Done With Gene Therapy Yet as New LGMD Asset Yields Promising Data Read More »
After the FDA revoked Sarepta Therapeutics’ platform designation in July, Krystal Biotech is “poised to be the first major beneficiary” of this program, according to analysts at William Blair.
FDA’s Second Platform Designation Goes to Krystal After Sarepta Withdrawal Read More »
The acquisition will give BioCryst an investigational injectable drug for hereditary angioedema, potentially complementing its FDA-approved oral drug Orladeyo.
BioCryst Snaps Up Fellow Angiodema Player Astria for $700M Read More »
Bristol Myers Squibb and insitro first partnered in 2020 to develop induced pluripotent stem cell models of amyotrophic lateral sclerosis and frontotemporal dementia. Last December, BMS exercised its option for an ALS target.
BMS Deepens ALS Alliance With Insitro, Puts $2B+ On the Line Read More »
Johnson & Johnson has yet to make a drug pricing deal with Trump; Novo makes more moves under new CEO; more than 1,000 laid off from CDC, though many immediately hired back; the BIOSECURE Act is back and more.
Q3 Earnings Are Here, Novo Ditches Cell Therapy but Buys Akero, Gov’t Shutdown Hits CDC Read More »
